Intellia Therapeutics
NTLA
349 hedge funds and large institutions have $4.71B invested in Intellia Therapeutics in 2022 Q1 according to their latest regulatory filings, with 61 funds opening new positions, 96 increasing their positions, 125 reducing their positions, and 77 closing their positions.
0.41% more ownership
Funds ownership: 86.76% → 87.17% (+0.41%)
6% less funds holding
Funds holding: 372 → 349 (-23)
15% less call options, than puts
Call options by funds: $44.3M | Put options by funds: $51.9M
21% less first-time investments, than exits
New positions opened: 61 | Existing positions closed: 77
23% less repeat investments, than reductions
Existing positions increased: 96 | Existing positions reduced: 125
33% less funds holding in top 10
Funds holding in top 10: 9 → 6 (-3)
38% less capital invested
Capital invested by funds: $7.64B → $4.71B (-$2.93B)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIM
ARK Investment Management
St. Petersburg,
Florida
|
+$90.2M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
+$75.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$47.1M |
| 4 |
Millennium Management
New York
|
+$41.5M |
| 5 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$91.7M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
-$71.6M |
| 3 |
Jennison Associates
New York
|
-$61.5M |
| 4 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$49.5M |
| 5 |
Adage Capital Partners
Boston,
Massachusetts
|
-$46.3M |
NTLA Hedge Fund Activity: Q1 2022 in Review
349 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q1 2022, worth a combined $4.71B — down 38% from $7.64B a quarter earlier.
Sellers outnumbered buyers: 77 funds closed out of NTLA and 61 opened new positions — a net loss of 16 holders — while 125 trimmed existing stakes and 96 added.
The largest buyer was ARK Investment Management, adding an estimated $90.2M. The largest seller was Fidelity Investments, cutting an estimated $91.7M.
- 349 institutional investors held Intellia Therapeutics (NTLA) as of Q1 2022, down from 372 in Q4 2021.
- Funds reported $4.71B of Intellia Therapeutics stock for Q1 2022, down 38% quarter-over-quarter.
- 61 funds opened new Intellia Therapeutics positions in Q1 2022 and 77 closed out, a net change of -16 holders.
- The largest Intellia Therapeutics buyer in Q1 2022 was ARK Investment Management, an estimated $90.2M added.
- The largest Intellia Therapeutics seller in Q1 2022 was Fidelity Investments, an estimated $91.7M sold.
Based on aggregated 13F filings for Q1 2022.